April 26, 2016
Novocure’s Optune Now Available at More Than 360 Cancer Treatment Centers in the U.S.
Globally, more than 500 medical institutions can prescribe Optune to glioblastoma patients Globally, more than 500 medical institutions can prescribe Optune to glioblastoma patients April 26, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Physicians… Read More
learn more
April 26, 2016
Novocure’s Optune Now Available at More Than 360 Cancer Treatment Centers in the U.S.
Globally, more than 500 medical institutions can prescribe Optune to glioblastoma patients Globally, more than 500 medical institutions can prescribe Optune to glioblastoma patients April 26, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Physicians… Read More
learn more
April 26, 2016
Novocure’s Optune Now Available at More Than 360 Cancer Treatment Centers in the U.S.
Globally, more than 500 medical institutions can prescribe Optune to glioblastoma patients Globally, more than 500 medical institutions can prescribe Optune to glioblastoma patients April 26, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Physicians… Read More
learn more
April 25, 2016
FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma
The RTOG 3503 Phase 2 Trial is the First Consortium Study to Test Tumor Treating Fields Therapy The RTOG 3503 Phase 2 Trial is the First Consortium Study to Test Tumor Treating Fields Therapy April 25, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(… Read More
learn more
April 25, 2016
FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma
The RTOG 3503 Phase 2 Trial is the First Consortium Study to Test Tumor Treating Fields Therapy The RTOG 3503 Phase 2 Trial is the First Consortium Study to Test Tumor Treating Fields Therapy April 25, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(… Read More
learn more
April 25, 2016
FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma
The RTOG 3503 Phase 2 Trial is the First Consortium Study to Test Tumor Treating Fields Therapy The RTOG 3503 Phase 2 Trial is the First Consortium Study to Test Tumor Treating Fields Therapy April 25, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(… Read More
learn more
April 15, 2016
OpportunityAnalyzer: Glioblastoma – Opportunity Analysis and Forecasts to 2024 – Research and Markets
April 15, 2016 08:46 AM Eastern Daylight Time DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “OpportunityAnalyzer: Glioblastoma – Opportunity Analysis and Forecasts to 2024” report to their offering. Read More
learn more
April 15, 2016
OpportunityAnalyzer: Glioblastoma – Opportunity Analysis and Forecasts to 2024 – Research and Markets
April 15, 2016 08:46 AM Eastern Daylight Time DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “OpportunityAnalyzer: Glioblastoma – Opportunity Analysis and Forecasts to 2024” report to their offering. Read More
learn more
April 15, 2016
OpportunityAnalyzer: Glioblastoma – Opportunity Analysis and Forecasts to 2024 – Research and Markets
April 15, 2016 08:46 AM Eastern Daylight Time DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “OpportunityAnalyzer: Glioblastoma – Opportunity Analysis and Forecasts to 2024” report to their offering. Read More
learn more
April 7, 2016
Novocure to Present New Preclinical Data on Tumor Treating Fields at American Association for Cancer Research Annual Meeting 2016
New Findings Show TTFields May Be Optimized to Prevent Migration and Invasion of Glioma Cells New Findings Show TTFields May Be Optimized to Prevent Migration and Invasion of Glioma Cells April 07, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(… Read More
learn more
